EsonarimodAlternative Names: KE 298; Sonatimod
Latest Information Update: 12 Mar 2008
At a glance
- Originator Taisho Pharmaceutical
- Class Antirheumatics; Carboxylic acids; Small molecules
- Mechanism of Action Interleukin 1 inhibitors
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- Discontinued Rheumatoid arthritis